Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons.
about
The risk of elevated prolactin levels in pediatric patients exposed to antipsychotics for the treatment of schizophrenia and schizophrenia spectrum disorders: protocol for a systematic review and meta-analysisPharmacotherapy of bipolar disorder in children and adolescents: an updatePrevalence and correlates of antipsychotic polypharmacy in children and adolescents receiving antipsychotic treatmentAtypical antipsychotics in the treatment of early-onset schizophreniaEfficacy and safety of pharmacological and psychological interventions for the treatment of psychosis and schizophrenia in children, adolescents and young adults: a systematic review and meta-analysisEffectiveness of antipsychotics used in first-episode psychosis: a naturalistic cohort study.The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review.Preliminary and ongoing French multicenter prospective naturalistic study of adverse events of antipsychotic treatment in naive children and adolescents.Antidepressant and antipsychotic use in an Italian pediatric population.Plasma clozapine and norclozapine in relation to prescribed dose and other factors in patients aged <18 years: data from a therapeutic drug monitoring service, 1994-2010.Paediatric European Risperidone Studies (PERS): context, rationale, objectives, strategy, and challengesProfile of aripiprazole in the treatment of bipolar disorder in children and adolescentsA retrospective study of antipsychotic drug switching in a pediatric population.Prolactin variations during risperidone therapy in a sample of drug-naive children and adolescents.Elevated immune-inflammatory signaling in mood disorders: a new therapeutic target?Risk factors for neutropenia in clozapine-treated children and adolescents with childhood-onset schizophrenia.Incidence of adverse events in antipsychotic-naïve children and adolescents treated with antipsychotic drugs: a French multicentre naturalistic study protocol (ETAPE)Child neuropsychopharmacology: good news… the glass is half full.Metabolic Disturbances, Side Effect Profile and Effectiveness of Clozapine in Adolescents.Safety, tolerability, and efficacy of quetiapine in youth with schizophrenia or bipolar I disorder: a 26-week, open-label, continuation study.Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.Polypharmacy with antidepressants in children and adolescents.Weight gain and increase of body mass index among children and adolescents treated with antipsychotics: a critical review.Safety and pharmacokinetics of atypical antipsychotics in children and adolescents.The effects of second-generation antipsychotics on food intake, resting energy expenditure and physical activity.Practitioner review: Long-term pharmacological treatment of pediatric bipolar disorder.Weight gain and antipsychotics: a drug safety review.Do antipsychotics increase diabetes risk in children and adolescents?Long-Term Efficacy of Methylphenidate Immediate-Release for the Treatment of Childhood ADHD.Weight gain and obesity in schizophrenia: epidemiology, pathobiology, and management.Common Medications Which Lead to Unintended Alterations in Weight Gain or Organ Lipotoxicity.A review of the nutritional challenges experienced by people living with severe mental illness: a role for dietitians in addressing physical health gaps.Patterns of Antipsychotic Prescribing by Physicians to Young Children.Comparison of the effect of lithium plus quetiapine with lithium plus risperidone in children and adolescents with bipolar I disorder: a randomized clinical trial.First-episode psychosis is associated with oxidative stress: Effects of short-term antipsychotic treatment.Repeated aripiprazole treatment causes dopamine D2 receptor up-regulation and dopamine supersensitivity in young rats.Molecular Mechanisms of Antipsychotic Drug-Induced Diabetes.The effects of antipsychotics on weight gain, weight-related hormones and homocysteine in children and adolescents: a 1-year follow-up study.Relationship between antipsychotics and weight in patients with Prader-Willi syndrome.Change and dispersion of QT interval during treatment with quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: results from the TEA trial.
P2860
Q26996493-7F7D2840-6918-4B1D-B873-716B1187B393Q27027052-1838F945-9AD2-4914-9A59-45BF73FC8486Q27028197-D8E2B429-0EBC-40DA-AB20-C2925B322245Q28083361-30E999EF-57DB-4DBA-B85E-65DF6AD82D25Q28650054-97B49B98-C0E3-4323-96FC-52443D13788DQ30490166-61C3E4F7-4BB9-4206-9F7F-0185BF1F6D45Q33619940-F4C88217-5106-4AD0-BDE5-DBD65DFBE298Q33835596-EBCBE828-DA97-4C87-B983-6949D2E7E253Q33909185-C24B99BA-18AC-48BB-89BD-F512607AB1DFQ34322230-53AFABB8-FDDA-46D3-BE73-CD44C6507902Q34580449-9935200E-5016-4E86-A9BF-89643D160747Q34600500-18DC15A5-C42E-40E6-AE38-EA4372A8EA59Q35011070-41AEC9BB-481F-48B0-B1B7-2C2086895823Q35038921-A0B3DA4C-D1AF-4CD8-BA96-1DB485DB4B23Q36502629-BABF1329-684F-410C-9C20-32A36356616FQ36715883-DDBDC088-E6C5-4969-8236-7727EB47D7C8Q36773233-42187D4C-5B84-454F-AE75-C520C7515151Q36930870-C36BF35A-2372-48F3-B80B-361BEFE09C37Q36997233-976C2954-4CCC-4C5F-8418-56A863E1CD1EQ37187450-2046CA32-65FC-4B65-8665-32F520B726AAQ37947095-290D9893-64F1-4176-A3E6-F081DE6CD152Q38063355-DF5AAEBB-0A32-4811-A3B9-58BDF3AEE68AQ38090490-670B5E54-3204-42A0-9018-1A5C6B860922Q38099224-2B9525F9-15F0-493B-917F-76281FD07EA6Q38170310-ED354A06-768D-49F1-9B7B-44525FC03B7FQ38218213-E1F48A4A-9EF3-4687-A18E-1E600AC7CBD2Q38268590-AAA45D27-1CAD-4412-9C67-DE0FFBD7CE9AQ38283956-9A0C5144-F356-4213-8725-C061A35C2604Q38287037-FA694DEE-0D4B-4939-96AD-21DB5194D14BQ38504254-30F2ED58-775B-4AAF-AC30-52357E27FCE8Q38677949-E8C738F6-9AF0-44F4-BC63-2789131A01D1Q39248575-0E897645-9B41-4983-9676-D0F486404E15Q39600765-2AE2B60A-9A00-411D-8C2D-685918A822ABQ41686490-ABE51353-DD04-4EA4-AE07-22B274E373C1Q42479721-32A16751-5F05-465D-8C43-FB595DC20AFDQ45377706-62D6F628-2BE4-468D-AE70-68BFDB691BDBQ47165661-C9642281-3813-4807-B011-40B3F1CD675EQ47302269-0DB80575-88DA-4F82-B015-C02ACCF7C81DQ47397886-C51A301F-D7C9-4C9D-894B-9335B3321FDCQ47569717-2A8EFFA9-C67F-4A85-BF2B-8F0219AC7745
P2860
Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 10 August 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Efficacy and safety of second- ...... lacebo-controlled comparisons.
@en
Efficacy and safety of second- ...... lacebo-controlled comparisons.
@nl
type
label
Efficacy and safety of second- ...... lacebo-controlled comparisons.
@en
Efficacy and safety of second- ...... lacebo-controlled comparisons.
@nl
prefLabel
Efficacy and safety of second- ...... lacebo-controlled comparisons.
@en
Efficacy and safety of second- ...... lacebo-controlled comparisons.
@nl
P2093
P50
P921
P1476
Efficacy and safety of second- ...... lacebo-controlled comparisons.
@en
P2093
Christoph U Correll
Jessica Merchán-Naranjo
Mara Parellada
P304
P356
10.1016/J.EURONEURO.2010.07.002
P407
P577
2010-08-10T00:00:00Z